A. A. Ajazuddin, B. Amarji, and P. Kanaujia, Synthesis, characterization and in vitro studies of pegylated melphalan conjugates, Drug Dev. Ind. Pharm, vol.39, pp.1053-1062, 2013.

C. P. Anderson, K. K. Matthay, J. P. Perentesis, J. P. Neglia, H. H. Bailey et al., Pilot study of intravenous melphalan combined with continuous infusion L-S,R-buthionine sulfoximine for children with recurrent neuroblastoma, Pediatr. Blood Cancer, vol.62, pp.1739-1746, 2015.

K. S. Bottom, D. M. Ashley, H. S. Friedman, D. C. Longee, A. Moghrabi et al., Evaluation of Pre-radiotherapy Cyclophosphamide in Patients with Newly Diagnosed Glioblastoma Multiforme, J. Neurooncol, vol.46, pp.151-156, 2000.

W. Cao, Y. Gu, T. Li, and H. Xu, Ultra-sensitive ROS-responsive tellurium-containing polymers, Chem. Commun, vol.51, pp.7069-7071, 2015.

M. Chang, F. Zhang, T. Wei, T. Zuo, Y. Guan et al., Smart linkers in polymer-drug conjugates for tumor-targeted delivery, J. Drug Targeting, vol.24, pp.475-491, 2016.

I. Cobo, M. Li, B. S. Sumerlin, and S. Perrier, Smart hybrid materials by conjugation of responsive polymers to biomacromolecules, Nat. Mater, vol.14, pp.143-159, 2015.

M. Colvin, Alkylating Agents," in Holl.-Frei Cancer Med, 2003.

A. Cox, D. Vinciguerra, F. Re, R. D. Magro, S. Mura et al., Protein-functionalized nanoparticles derived from end-functional polymers and polymer prodrugs for crossing the blood-brain barrier, Eur. J. Pharm. Biopharm, vol.142, pp.70-82, 2019.
URL : https://hal.archives-ouvertes.fr/hal-02323861

J. T. Duskey, D. Belletti, F. Pederzoli, M. A. Vandelli, F. Forni et al., Current Strategies for the Delivery of Therapeutic Proteins and Enzymes to Treat Brain Disorders, Int. Rev. Neurobiol, vol.137, pp.1-28, 2017.

F. El-mohtadi, R. Arcyi, and N. Tirelli, Oxidation-responsive materials: biological rationale, state of the art, multiple responsiveness, and open issues, 2019.

, Macromol. Rapid Commun, vol.40, p.1800699

O. C. Farokhzad and R. Langer, Nanomedicine: Developing smarter therapeutic and diagnostic modalities, Adv. Drug Deliv. Rev, vol.58, pp.1456-1459, 2006.

S. Gahramanov, C. Varallyay, R. M. Tyson, C. Lacy, R. Fu et al., Diagnosis of pseudoprogression using MRI perfusion in patients with glioblastoma multiforme may predict improved survival, CNS Oncol, vol.3, pp.389-400, 2014.

M. R. Gill and K. A. Vallis, Transition metal compounds as cancer radiosensitizers, Chem. Soc Rev, vol.48, pp.540-557, 2019.

A. Gonda, N. Zhao, J. V. Shah, H. R. Calvelli, H. Kantamneni et al., Engineering Tumor-Targeting Nanoparticles as Vehicles for Precision Nanomedicine, vol.4, p.190021, 2019.

D. Gramatzki, C. Herrmann, C. Happold, K. A. Becker, E. Gulbins et al., Glioma Cell Death Induced by Irradiation or Alkylating Agent Chemotherapy Is Independent of the Intrinsic Ceramide Pathway, PloS One, vol.8, issue.5, p.63527, 2013.

C. P. Haar, P. Hebbar, G. C. Wallace, A. Das, W. A. Vandergrift et al., Drug Resistance in Glioblastoma: A Mini Review, Neurochem. Res, vol.37, pp.1192-1200, 2012.

H. Hagen, P. Marzenell, E. Jentzsch, F. Wenz, M. R. Veldwijk et al., Aminoferrocene-based prodrugs activated by reactive oxygen species, J. Med. Chem, vol.55, pp.924-934, 2012.

E. Hwang, S. Sim, S. H. Park, K. D. Song, H. Lee et al., , 2018.

, Anti-proliferative effect of Zea mays L. cob extract on rat C6 glioma cells through regulation of glycolysis, mitochondrial ROS, and apoptosis, Biomed. Pharmacother, vol.98, pp.726-732

A. Kühne, M. V. Tzvetkov, Y. Hagos, H. Lage, G. Burckhardt et al., Influx and efflux transport as determinants of melphalan cytotoxicity: Resistance to melphalan in MDR1 overexpressing tumor cell lines, Biochem. Pharmacol, vol.78, pp.45-53, 2009.

K. Kawamura, F. Qi, and J. Kobayashi, Potential relationship between the biological effects of low-dose irradiation and mitochondrial ROS production, J. Radiat. Res. (Tokyo), vol.59, pp.91-97, 2018.

E. Kim, S. Bhuniya, H. Lee, H. M. Kim, C. Cheong et al., An Activatable Prodrug for the Treatment of Metastatic Tumors, J. Am. Chem. Soc, vol.136, pp.13888-13894, 2014.

A. Kirtane, S. Kalscheuer, and J. Panyam, Exploiting Nanotechnology to Overcome Tumor Drug Resistance: Challenges and Opportunities, Adv. Drug Deliv. Rev, vol.65, pp.1731-1747, 2013.

M. Kuczma, Z. Ding, and G. Zhou, Immunostimulatory Effects of Melphalan and Usefulness in Adoptive Cell Therapy with Antitumor CD4+ T Cells, Crit. Rev. Immunol, vol.36, pp.179-191, 2016.

L. Kupczyk-subotkowska, T. J. Siahaan, A. S. Basile, H. S. Friedman, P. E. Higgins et al., Modulation of Melphalan Resistance in Glioma Cells with a Peripheral Benzodiazepine Receptor Ligand-Melphalan Conjugate, J. Med. Chem, vol.40, pp.1726-1730, 1997.

E. J. Kwon, J. H. Lo, and S. N. Bhatia, Smart nanosystems: Bio-inspired technologies that interact with the host environment, Proc. Natl. Acad. Sci, vol.112, pp.14460-14466, 2015.

B. Lee, T. Amano, H. Q. Wang, J. L. Pantoja, C. W. Yoon et al., Reactive oxygen species responsive nanoprodrug to treat intracranial glioblastoma, ACS Nano, vol.7, pp.3061-3077, 2013.

C. Legendre, S. Avril, C. Guillet, and E. Garcion, Low oxygen tension reverses antineoplastic effect of iron chelator deferasirox in human glioblastoma cells, BMC Cancer, vol.16, p.51, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01388820

K. Lenting, R. Verhaak, M. Ter-laan, P. Wesseling, and W. Leenders, Glioma: experimental models and reality, Acta Neuropathol. (Berl.), vol.133, pp.263-282, 2017.

Q. Li, Y. Wen, X. You, F. Zhang, V. Shah et al., Development of a reactive oxygen species (ROS)-responsive nanoplatform for targeted oral cancer therapy, J. Mater. Chem. B, vol.4, pp.4675-4682, 2016.

S. Li, A. Xie, H. Li, X. Zou, and Q. Zhang, A self-assembled, ROSresponsive Janus-prodrug for targeted therapy of inflammatory bowel disease, J. Controlled Release, vol.316, pp.66-78, 2019.

J. Lin, D. A. Raoof, D. G. Thomas, J. K. Greenson, T. J. Giordano et al., L-Type Amino Acid Transporter-1 Overexpression and Melphalan Sensitivity in Barrett's Adenocarcinoma, Neoplasia, vol.6, pp.74-84, 2004.

D. Liu, F. Yang, F. Xiong, and N. Gu, The Smart Drug Delivery System and Its Clinical Potential, Theranostics, vol.6, pp.1306-1323, 2016.

X. Lu, G. Mestres, V. P. Singh, P. Effati, J. Poon et al., Selenium-and Tellurium-Based Antioxidants for Modulating Inflammation and Effects on Osteoblastic Activity, Antioxidants, vol.6, p.13, 2017.

N. Ma, H. Xu, L. An, J. Li, Z. Sun et al., Radiation-Sensitive Diselenide Block Co-polymer Micellar Aggregates: Toward the Combination of Radiotherapy and Chemotherapy, Langmuir, vol.27, pp.5874-5878, 2011.

E. Mahase, Cancer overtakes CVD to become leading cause of death in high income countries, BMJ, vol.366, p.5368, 2019.

P. Majewska, S. Ioannidis, M. H. Raza, N. Tanna, H. Bulbeck et al., Postprogression survival in patients with glioblastoma treated with concurrent chemoradiotherapy: a routine care cohort study, CNS Oncol, vol.6, pp.307-313, 2017.

K. D. Mccarthy and J. De-vellis, Preparation of separate astroglial and oligodendroglial cell cultures from rat cerebral tissue, J. Cell Biol, vol.85, pp.890-902, 1980.

K. J. Mckelvey, A. L. Hudson, M. Back, T. Eade, and C. I. Diakos, Radiation, inflammation and the immune response in cancer, Mamm. Genome, vol.29, pp.843-865, 2018.

R. Meel, . Van-der, E. Sulheim, Y. Shi, F. Kiessling et al., Smart cancer nanomedicine, Nat. Nanotechnol, vol.14, pp.1007-1017, 2019.

A. Najer, S. Thamboo, J. T. Duskey, C. G. Palivan, H. Beck et al., Analysis of Molecular Parameters Determining the Antimalarial Activity of Polymer-Based Nanomimics, Macromol. Rapid Commun, vol.36, pp.1923-1928, 2015.

L. Nam, C. Coll, L. C. Erthal, C. De-la-torre, D. Serrano et al., Drug Delivery Nanosystems for the Localized Treatment of Glioblastoma Multiforme, Materials, vol.11, p.779, 2018.

H. Nawashiro, N. Otani, Y. Uozumi, H. Ooigawa, T. Toyooka et al., L-type amino acid transporter 1 as a potential molecular target in human astrocytic tumors, Brain Tumor Pathol, vol.22, pp.484-492, 2005.

N. Oddone, N. Lecot, M. Ferna?dez, A. Rodriguez-haralambides, P. Cabral et al., In vitro and in vivo uptake studies of PAMAM G4.5 dendrimers in breast cancer, J. Nanobiotechnol, vol.14, p.45, 2016.

N. Oddone, F. Pederzoli, J. T. Duskey, C. A. De-benedictis, A. M. Grabrucker et al., ROS-responsive "smart" polymeric conjugate: Synthesis, characterization and proof-of-concept study, Int. J. Pharm, vol.570, p.118655, 2019.

P. Pei, C. Sun, W. Tao, J. Li, X. Yang et al., ROS-sensitive thioketal-linked polyphosphoester-doxorubicin conjugate for precise phototriggered locoregional chemotherapy, Biomaterials, vol.188, pp.74-82, 2019.

H. Pelicano, D. Carney, and P. Huang, ROS stress in cancer cells and therapeutic implications, Drug Resist. Updat, vol.7, pp.97-110, 2004.

D. Raucher, S. Dragojevic, and J. Ryu, Macromolecular Drug Carriers for Targeted Glioblastoma Therapy: Preclinical Studies, Challenges, and Future Perspectives, Front. Oncol, vol.17, p.624, 2018.

S. Regmi, S. Pathak, M. R. Nepal, P. Shrestha, J. Park et al., Inflammation-triggered local drug release ameliorates colitis by inhibiting dendritic cell migration and Th1/Th17 differentiation, J. Controlled Release, vol.316, pp.138-149, 2019.

F. F. Resende, S. S. Titze-de-almeida, and R. Titze-de-almeida, Function of neuronal nitric oxide synthase enzyme in temozolomideinduced damage of astrocytic tumor cells, Oncol. Lett, vol.15, pp.4891-4899, 2018.

L. Rigon, M. Salvalaio, F. Pederzoli, E. Legnini, J. T. Duskey et al., Targeting Brain Disease in MPSII: Preclinical Evaluation of IDS-Loaded PLGA Nanoparticles, Int. J. Mol. Sci, vol.20, 2019.

B. Sampaio-maia, M. P. Serrão, and P. Soares-da-silva, Regulatory pathways and uptake ofl-DOPA by capillary cerebral endothelial cells, astrocytes, and neuronal cells, Am. J. Physiol. Cell Physiol, vol.280, pp.333-342, 2001.

V. Sharma, C. Joseph, S. Ghosh, A. Agarwal, M. K. Mishra et al., Kaempferol induces apoptosis in glioblastoma cells through oxidative stress, Mol. Cancer Ther, vol.6, pp.2544-2553, 2007.

M. S. Shim and Y. Xia, A Reactive Oxygen Species (ROS)-Responsive Polymer for Safe, Efficient, and Targeted Gene Delivery in Cancer Cells, Angew. Chem. Int. Ed, vol.52, pp.6926-6929, 2013.

F. Sousa, H. K. Dhaliwal, F. Gattacceca, B. Sarmento, and M. M. Amiji, Enhanced anti-angiogenic effects of bevacizumab in glioblastoma treatment upon intranasal administration in polymeric nanoparticles, J. Controlled Release, vol.309, pp.37-47, 2019.
URL : https://hal.archives-ouvertes.fr/hal-02533340

T. G. Souza, V. S. Ciminelli, and N. D. Mohallem, A comparison of TEM and DLS methods to characterize size distribution of ceramic nanoparticles, J. Phys. Conf. Ser, vol.733, p.12039, 2016.

C. Sun, Y. Liang, N. Hao, L. Xu, F. Cheng et al., A ROSresponsive polymeric micelle with a p-conjugated thioketal moiety for enhanced drug loading and efficient drug delivery, Org. Biomol. Chem, vol.15, pp.9176-9185, 2017.

M. Swierczewska, K. C. Lee, and S. Lee, What is the future of PEGylated therapies?, Expert Opin. Emerg. Drugs, vol.20, pp.531-536, 2015.

V. Taresco, C. Alexander, N. Singh, P. , and A. K. , Stimuli-Responsive Prodrug Chemistries for Drug Delivery, Adv. Ther, vol.1, p.1800030, 2018.

G. Tosi, F. Pederzoli, D. Belletti, M. A. Vandelli, F. Forni et al., Nanomedicine in Alzheimer's disease: Amyloid beta targeting strategy, Prog. Brain Res, vol.245, pp.57-88, 2019.

C. Tsai, W. Yeh, S. M. Huang, T. Tan, and D. Lu, Wogonin Induces Reactive Oxygen Species Production and Cell Apoptosis in Human Glioma Cancer Cells, Int. J. Mol. Sci, vol.13, pp.9877-9892, 2012.

Y. Tseng, Y. Wang, C. Su, T. Yang, T. Chang et al., Concurrent delivery of carmustine, irinotecan, and cisplatin to the cerebral cavity using biodegradable nanofibers: In vitro and in vivo studies, Colloids Surf. B Biointerf, vol.134, pp.254-261, 2015.

L. Wang, F. Fan, W. Cao, and H. Xu, Ultrasensitive ROS-Responsive Coassemblies of Tellurium-Containing Molecules and Phospholipids, ACS Appl. Mater. Interf, vol.7, pp.16054-16060, 2015.

D. Wang, C. Wang, L. Wang, C. , and Y. , A comprehensive review in improving delivery of small-molecule chemotherapeutic agents overcoming the blood-brain/brain tumor barriers for glioblastoma treatment, Drug Deliv, vol.26, pp.551-565, 2019.

Y. Wang, Y. Zhang, Z. Ru, W. Song, L. Chen et al., A ROSresponsive polymeric prodrug nanosystem with self-amplified drug release for PSMA (-) prostate cancer specific therapy, J. Nanobiotechnol, vol.17, p.91, 2019.

U. H. Weidle, G. Tiefenthaler, G. , and G. , Proteases as Activators for Cytotoxic Prodrugs in Antitumor Therapy, Cancer Genom. Proteomics, vol.11, pp.67-79, 2014.

A. Wojtala, M. Bonora, D. Malinska, P. Pinton, J. Duszynski et al., Chapter Thirteen -Methods to Monitor ROS Production by Fluorescence Microscopy and Fluorometry, Methods in Enzymology Conceptual Background and Bioenergetic/Mitochondrial Aspects of Oncometabolism, pp.243-262, 2014.

T. Xiong, H. Wei, X. Chen, X. , and H. , ADP-ribose) polymerase (PARP) inhibitor, reverses melphalan-resistance and inhibits repair of DNA double-strand breaks by targeting the FA/BRCA pathway in multidrug resistant multiple myeloma cell line RPMI8226/R, PJ34, a poly, vol.46, pp.223-232, 2015.

X. Xu, P. E. Saw, W. Tao, Y. Li, X. Ji et al., ROS-Responsive Polyprodrug Nanoparticles for Triggered Drug Delivery and Effective Cancer Therapy, Adv. Mater. Deerfield Beach Fla, vol.29, p.1700141, 2017.

T. Yamamori, H. Yasui, M. Yamazumi, Y. Wada, Y. Nakamura et al., Ionizing radiation induces mitochondrial reactive oxygen species production accompanied by upregulation of mitochondrial electron transport chain function and mitochondrial content under control of the cell cycle checkpoint. Free Radic, Biol. Med, vol.53, pp.260-270, 2012.

J. Yang, Y. Li, T. Zhang, and X. Zhang, Development of bioactive materials for glioblastoma therapy, Bioact. Mater, vol.1, pp.29-38, 2016.

C. Yue, Y. Yang, C. Zhang, G. Alfranca, S. Cheng et al., ROS-Responsive Mitochondria-Targeting Blended Nanoparticles: Chemo-and Photodynamic Synergistic Therapy for Lung Cancer with On-Demand Drug Release upon Irradiation with a, Single Light Source. Theranostics, vol.6, pp.2352-2366, 2016.

Y. Zeng, J. Ma, Y. Zhan, X. Xu, Q. Zeng et al., Hypoxiaactivated prodrugs and redox-responsive nanocarriers, Int. J. Nanomed, vol.13, pp.6551-6574, 2018.

R. Zhang, X. Qin, F. Kong, P. Chen, and G. Pan, Improving cellular uptake of therapeutic entities through interaction with components of cell membrane, Drug Deliv, vol.26, pp.328-342, 2019.

M. Zheng, Y. Liu, Y. Wang, D. Zhang, Y. Zou et al., ROS-Responsive Polymeric siRNA Nanomedicine Stabilized by Triple Interactions for the Robust Glioblastoma Combinational RNAi Therapy, Adv. Mater, vol.0, 2019.